Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), Teva Pharmaceutical (TEVA) and Medtronic (MDT)

Tipranks - Tipranks - Fri May 23, 2025

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ginkgo Bioworks Holdings (DNA – Research Report), Teva Pharmaceutical (TEVA – Research Report) and Medtronic (MDT – Research Report).

Confident Investing Starts Here:

Ginkgo Bioworks Holdings (DNA)

In a report released today, Matt Larew from William Blair maintained a Sell rating on Ginkgo Bioworks Holdings. The company’s shares closed last Wednesday at $7.40, close to its 52-week low of $5.26.

According to TipRanks.com, Larew is a 1-star analyst with an average return of -6.9% and a 38.0% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Option Care Health. ;'>

Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Moderate Sell with an average price target of $9.17, which is a 16.7% upside from current levels. In a report issued on May 13, BTIG also reiterated a Sell rating on the stock with a $6.00 price target.

See the top stocks recommended by analysts >>

Teva Pharmaceutical (TEVA)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Teva Pharmaceutical, with a price target of $22.00. The company’s shares closed last Wednesday at $16.55.

According to TipRanks.com, Gerberry is a 4-star analyst with an average return of 2.4% and a 49.0% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Arrowhead Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $24.00 average price target, a 43.9% upside from current levels. In a report issued on May 12, J.P. Morgan also upgraded the stock to Buy with a $23.00 price target.

Medtronic (MDT)

BTIG analyst Ryan Zimmerman maintained a Hold rating on Medtronic yesterday. The company’s shares closed last Wednesday at $84.41.

According to TipRanks.com, Zimmerman has 0 stars on 0-5 stars ranking scale with an average return of -3.2% and a 40.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Treace Medical Concepts, and Organogenesis Holdings. ;'>

Currently, the analyst consensus on Medtronic is a Moderate Buy with an average price target of $96.21, representing an 11.1% upside. In a report issued on May 19, Needham also maintained a Hold rating on the stock.

Read More on DNA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).